Panbela Therapeutics (Panbela Therapeutics) Total Liabilities : $13.71 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Total Liabilities?

Panbela Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $13.71 Mil.

Panbela Therapeutics's quarterly Total Liabilities increased from Sep. 2023 ($13.11 Mil) to Dec. 2023 ($16.51 Mil) but then declined from Dec. 2023 ($16.51 Mil) to Mar. 2024 ($13.71 Mil).

Panbela Therapeutics's annual Total Liabilities increased from Dec. 2021 ($2.66 Mil) to Dec. 2022 ($13.03 Mil) and increased from Dec. 2022 ($13.03 Mil) to Dec. 2023 ($16.51 Mil).

Panbela Therapeutics Total Liabilities Historical Data

The historical data trend for Panbela Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics Total Liabilities Chart

Panbela Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1.76

1.37

2.66

13.03

16.51

Panbela Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															13.94	14.75	13.11	16.51	13.71

Panbela Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Panbela Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.318	+	(4.194	+	8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	16.51

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11.802	-	-4.71
	=	16.51

Panbela Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.519	+	(3.194	+	-8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	13.71

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	10.527	-	-3.186
	=	13.71

Panbela Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Panbela Therapeutics (Panbela Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Executives

Jennifer K. Simpson	director, officer: President and CEO	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath	officer: V.P. of Finance & CFO	4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob	director	712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer	director	712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust	10 percent owner	1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson	10 percent owner	130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel	director	712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill	director	712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen	officer: Chief Financial Officer	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen	director	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr	director
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen	director	712 VISTA BLVD, #305, WACONIA MN 55387